A 28-year-old female presents with a depressive episode. She has previously been hospitalized and treated for manic episode, but is not currently taking any medication. Practice guidelines indicate preferential use of which of the following to treat bipolar depression?

A. Lamotrigine, Quetiapine: Both lamotrigine and quetiapine are evidence-based first-line treatments for bipolar depression. Lamotrigine is particularly effective for depressive episodes with a low risk of inducing mania, while quetiapine provides both antidepressant and antipsychotic benefits. B. Quetiapine, Olanzapine: While quetiapine is effective for bipolar depression, olanzapine alone is less effective for depressive symptoms. Olanzapine is often combined with fluoxetine for depression, but this combination is not a first-line. C. Lithium, Valproate: Lithium has strong efficacy in preventing mania and reducing suicide risk but is less effective for acute bipolar depression. Valproate primarily targets manic episodes rather than depressive phases. D. Valproate, Lamotrigine: Lamotrigine is effective for depression, but valproate has limited antidepressant efficacy. Using valproate for acute bipolar depression is not guideline-preferred unless there is mixed or rapid-cycling presentation.